Cagrilintide: Amylin Analog Weight Loss Guide

Every weight loss peptide you've heard of targets the incretin pathway. GLP-1. GIP. Glucagon. Cagrilintide takes a completely different route. It mimics amylin, a hormone your pancreas releases alongside insulin after meals. And the clinical data suggests this alternative approach has real potential.

What amylin does (and why you should care)

Amylin is co-secreted with insulin from pancreatic beta cells every time you eat. Its job: slow gastric emptying, suppress glucagon release, and signal satiety to the brain through the area postrema (a part of the brainstem that sits outside the blood-brain barrier).

In people with obesity, amylin signaling is often disrupted. The satiety message gets weaker. You finish a meal and 45 minutes later you're thinking about food again.

Cagrilintide is a long-acting amylin analog. It restores that signal, but lasts much longer than natural amylin (which has a half-life of about 13 minutes). One weekly injection.

How it differs from GLP-1 agonists

GLP-1 agonists (tirzepatide, semaglutide, retatrutide) work through incretin receptors. They delay gastric emptying and suppress appetite through hypothalamic signaling.

Cagrilintide works through amylin receptors (AMY1, AMY2, AMY3) and calcitonin receptors. Different receptors, different brain regions, different signaling cascade. The satiety mechanism overlaps somewhat with GLP-1 (both reduce appetite), but the pathways are distinct.

Why does this matter? Because people who plateau on GLP-1 peptides might respond to amylin agonism. Different receptor, different response curve. Novo Nordisk is betting on this with their CagriSema combination (cagrilintide + semaglutide), which showed up to 25% weight loss in Phase II trials combining both pathways.

Clinical data

Phase II trial (Lau et al., Lancet, 2021): 706 participants, 26 weeks.

• Cagrilintide alone at 4.5mg: approximately 10.8% weight loss
• Placebo: 3%
• Dose-dependent response across all arms

The CagriSema combination trial (Phase II, 2023): cagrilintide + semaglutide together produced weight loss exceeding either compound alone. Eli Lilly's triple agonist approach (retatrutide) competes with this, but through different biology.

Phase III for CagriSema is ongoing. For cagrilintide as a standalone, the data is Phase II level. Promising, but not yet confirmed in large-scale Phase III.

Dosing

Weekly subcutaneous injection. The Phase II trial tested doses from 0.3mg to 4.5mg, with titration over 4-8 weeks. Higher doses showed better weight loss but more GI side effects during escalation.

[[Cagrilintide|12]] is available in 5mg and 10mg vials. Reconstitute with bacteriostatic water. Standard subcutaneous injection technique.

Side effects

GI symptoms dominate: nausea (30-40% in higher dose groups), diarrhea, vomiting. Similar pattern to GLP-1 agonists, similar solution (titrate slowly). Injection site reactions were reported in about 5-10% of participants.

One difference from GLP-1 peptides: amylin analogs can cause hypoglycemia more easily in certain contexts (especially if combined with insulin). For research purposes, blood glucose monitoring is worth considering.

Who this is for

If you've tried GLP-1 agonists and plateaued. If you're interested in targeting a completely different receptor pathway. If the combination approach (amylin + incretin) interests you as a research direction. [[Cagrilintide|12]] gives you access to the amylin side of the equation.

Questions about dosing or combining with other peptides? Reach out to us.

This article is for educational purposes. Peptides are intended for research use. Consult a healthcare professional before starting any protocol.